Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Centaur, Inc.
WARNING LETTER
•Centaur, Inc.•June 26, 2009

Centaur, Inc. – FDA Warning Letter, Jun 26, 2009

Record Details

The FDA issued a Warning Letter to Centaur, Inc. following an inspection from June 17-26, 2009, at their Olathe, KS facility. The inspection revealed numerous violations of current Good Manufacturing Practice (cGMP) regulations, specifically 21 C.F.R. Parts 210 and 211, rendering their drug products adulterated under section 501(a)(2)(B) of the Federal Food, Drug and Cosmetic Act. Key deficiencies included the failure to maintain written records of investigations into unexplained discrepancies (21 C.F.R. 211.192), inadequate employee education and training documentation (21 C.F.R. 211.25(a)), and lack of a second person's review for accuracy and completeness of original records (21 C.F.R 211.194(a)(8)). Additionally, the firm failed to follow written quality control unit procedures (21 C.F.R. 211.22(d)), properly identify and control rejected in-process materials (21 C.F.R. 211.110(d)), and provide adequate equipment for humidity and temperature control in the warehouse, critical for drug products requiring controlled storage (21 C.F.R. 211.46(b)). The FDA noted these issues indicate serious problems in the firm's quality assurance and laboratory systems, with some observations being repeat violations from prior inspections in 2003, 2005, and 2007. Centaur, Inc. must promptly investigate and correct these violations, providing a detailed response within fifteen working days outlining corrective actions, recurrence prevention plans, and quality system changes. Failure to comply could lead to regulatory actions like seizure or injunction, and impact federal contract awards. The FDA acknowledged the firm's initial response but requested more specific documentation.

Company
Centaur, Inc.
Inspection date
June 26, 2009
Product type
Drugs
Office
Kansas City District Office
People
  • John W. Thorsky (District Director)
  • Matthew A. Walburger (Compliance Officer)
View Company Profile

ID · 6b969ad9-5530-48a1-89be-7980e17a6d88

Violation Codes9
21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.25(a)21 CFR 211.194(a)(8)21 CFR 211.22(d)21 CFR 211.110(d)21 CFR 211.46(b)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Centaur, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.